S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Eradication of minimal residual disease in hairy cell leukemia
Farhad Ravandi,Jeffrey L. Jorgensen,Susan O'Brien,Srdan Verstovsek,Charles Koller,Stefan Faderl,Francis J. Giles,Alessandra Ferrajoli,William G. Wierda,Shirley Odinga,Xuelin Huang,Deborah A. Thomas,Emil J. Freireich,Dan Jones,Michael J. Keating,Hagop M. Kantarjian +15 more
TL;DR: It is concluded that eradication of MRD in HCL is possible and whether this leads to a reduced risk of relapse would need to be evaluated in a larger number of patients and with longer follow-up.
Journal ArticleDOI
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Jorge E. Cortes,Moshe Talpaz,Susan O'Brien,Stefan Faderl,Guillermo Garcia-Manero,Alessandra Ferrajoli,Srdan Verstovsek,Mary Beth Rios,Jenny Shan,Hagop M. Kantarjian +9 more
TL;DR: The authors investigated the significance of the WHO classification system and compared it with the classification systems used to date in imatinib trials (“standard definition”) to determine its impact in establishing the outcome of patients after therapy withImatinib.
Journal ArticleDOI
Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia
Alison Gardner,Gloria Mattiuzzi,Stefan Faderl,Gautam Borthakur,Guillermo Garcia-Manero,Sherry Pierce,Mark Brandt,Elihu H. Estey +7 more
TL;DR: In patients treated in a PE, a neutropenic diet did not prevent major infection or death.
Journal Article
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Hagop M. Kantarjian,Susan O'Brien,Jorge E. Cortes,Terry L. Smith,Mary Beth Rios,Jianqin Shan,Ying Yang,Francis J. Giles,Deborah A. Thomas,Stefan Faderl,Guillermo Garcia-Manero,Sima Jeha,William G. Wierda,Jean Pierre J. Issa,Steven M. Kornblau,Michael J. Keating,Debra Resta,Renaud Capdeville,Moshe Talpaz +18 more
TL;DR: Imatinib mesylate was active against Ph-positive, accelerated-phase CML, and the prognostic factors identified in this study could aid in tailoring treatment strategies to specific risk groups.
Journal ArticleDOI
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study
Steven M. Kornblau,Deborah E. Banker,Derek L. Stirewalt,Danny D. Shen,Elizabeth Lemker,Srdan Verstovsek,Zeev Estrov,Stefan Faderl,Jorge E. Cortes,Miloslav Beran,C. Ellen Jackson,Wenjing Chen,Elihu H. Estey,Frederick R. Appelbaum +13 more
TL;DR: Addition of PV to Ida-HDAC was safe, and the encouraging response rates support conducting further trials evaluating the effect of cholesterol modulation on response in AML.